Zevra Therapeutics, Inc.
ZVRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Zevra Therapeutics, Inc. focuses on Biotechnology services and products. Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. With a market capitalization of $565.9M, it sits in small-cap territory. The company develops its products through Ligand Activated Technology platform.
Market Cap
$565.9M
Beta
0.98
P/E (TTM)
10.36
P/E (Fwd)
8.85
EPS (TTM)
$0.92
EPS (Fwd)
$1.08
ROE
34.8%
ROA
8.7%
Cash
$221.6M
Total Debt
$1.5M
Free CF
$48.4M
52W Change
-14.0%
Annual Financials
Cash vs Debt
Where ZVRA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ZVRA finished 11.64% below its 150-day moving average ($11.25) and 6.84% below its 200-day moving average ($10.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZVRA overbought or oversold?
At the October 19, 2026 close, ZVRA's RSI(14) was 34.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $221.6M in cash and $1.5M in debt, ZVRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $48.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 34.8% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $10.2M (2022) to $106.5M (2025), reflecting a 948% increase over the period.
With cash comfortably exceeding debt, ZVRA has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zevra Therapeutics, Inc. and its sector.